TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06805825: A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

Sponsor: Novelty Nobility, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 67 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$4,775,232

Rescue Site Savings

+$3,141,600

Unlock Full NCT06805825 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06805825 Rescue Dossier →